Business

Gilead’s remdesivir showed no benefit in the European trial; No fetal risk was observed with vaccination during the first trimester. According to Reuters



© Reuters. The pharmaceutical company Gilead Sciences Inc.

By Nancy Lapid

(Dan Tri) – The following is a summary of some recent studies on COVID-19. These include research that warrants further research to corroborate the findings and have not been co-certified.

Two promising drugs for COVID-19 fail to deliver

Two drugs that look like promising treatments for COVID-19 in preliminary studies – remdesivir for hospitalized patients and hemostatics for patients who are not critically ill – have shown no benefit in those groups in randomized controlled trials, the researchers reported in two separate articles.

In five European countries, researchers studied 843 COVID-19 patients hospitalized between March 2020 and January 2021 and who needed oxygen or machines to help breathe. Two weeks after the patient received the Gilead Sciences (NASDAQ:) antiviral Remdesivir – sold under the brand name Veklury – plus standard of care or standard of care alone for up to 10 days, with no adverse reactions. group differences in signs of improvement, the investigators reported on Thursday.

In Japan between November 2020 and March 2021, researchers randomly assigned 155 patients with mild or moderate COVID-19 to receive the pancreatitis drug mesylat from Ono Pharmaceutical. Co or placebo for up to 14 days. Camostat blocks an enzyme that helps certain versions of the coronavirus infect cells – including variants circulating at the time of the study – but doesn’t help patients clear the virus in their airways faster than a placebo , Japanese researchers reported Saturday. They said the results “highlight … the need to conduct well-designed studies to confirm whether preclinical findings translate into meaningful clinical effects.” Both studies were posted on medRxiv prior to peer review.

COVID-19 vaccine in the first trimester of pregnancy appears to be safe

Preliminary data suggest that getting the COVID-19 vaccine during the first trimester of pregnancy does not increase the risk of birth defects in the fetus.

Researchers at Northwestern University School of Medicine (NASDAQ:) in Chicago studied 1,149 women who received at least one dose of the vaccine from Moderna (NASDAQ:), Pfizer/BioNTech or Johnson & Johnson (NYSE:) between 30 days before conception and 14 weeks gestation, which is the time when the fetus is most susceptible to birth defects caused by the mother medicine. Compared with 2,007 pregnant women who were still unvaccinated or vaccinated later, women who were vaccinated shortly before or early in pregnancy did not have a higher risk of fetal malformations detected by doctors during pregnancy tests. ultrasound examination, according to a report released Monday. in JAMA Pediatrics.

The authors acknowledge that ultrasound fetal screening is not as reliable as newborn screening, and since many of the women they studied are still pregnant, there is no real evidence for its safety. Vaccination during the first trimester requires larger studies of neonates.

SARS-CoV-2 infects eye cells in vitro

Lab experiments show that the coronavirus that causes COVID-19 can infect the cells that process vision in the eye and reproduce there.

The researchers used human cells in a test tube to grow a miniaturized, simplified version of the retina – the nerve tissue at the back of the eye that receives images and sends them as electrical signals to the brain. When the researchers exposed these “organoids” to SARS-CoV-2, the virus infected a variety of retinal neurons that perform different functions. Furthermore, the virus can make copies of itself in those cells, the researchers reported in the journal Stem Cell Reports. The researchers also found that in the infected organoids, genes that increase levels of inflammatory proteins associated with retinal damage were more active. They also found that younger retinal cells were more susceptible to virus attack, possibly because younger cells had more proteins on the surface that the virus used as a gateway to enter. .

Further experiments showed that the antibodies block those portals and make it harder for the virus to infect cells to protect retinal organelles. The findings suggest that the persistent syndrome known as persistent COVID may also include retinal problems, the researchers said.

Click to see a Reuters image https://tmsnrt.rs/3c7R3Bl of a vaccine in development.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor is it accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but by market makers, so prices may be inaccurate and subject to change. differs from the actual market price, which means that the price is indicative only and is not suitable for trading purposes. Therefore, Fusion Media does not accept any responsibility for any trading losses you may incur as a result of using this data.

Fusion Media or anyone associated with Fusion Media shall not bear any liability for loss or damage resulting from reliance on information including data, quotes, charts and buy/sell signals contained in this site. Please be fully informed of the risks and costs associated with trading in financial markets, which are among the riskiest forms of investment possible.



Source link

news7d

News 7D: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button